| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FIGF; VEGF-D |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human VEGFD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于VEGFD抗体的模拟参考文献示例(内容为概括性描述，非真实文献)：
---
1. **文献名称**: *VEGFD-Specific Antibody Inhibits Lymphatic Metastasis in Mouse Models*
**作者**: Smith A, et al.
**摘要**: 该研究开发了一种高特异性抗VEGFD单克隆抗体，证明其能有效阻断VEGFD与VEGFR3结合，抑制肿瘤细胞诱导的淋巴管生成，并在乳腺癌小鼠模型中显著减少淋巴结转移。
2. **文献名称**: *Therapeutic Targeting of VEGFD in Inflammatory Diseases*
**作者**: Lee H, et al.
**摘要**: 通过抗VEGFD抗体干预慢性炎症模型，研究发现该抗体可减少病理性淋巴管扩张和炎症细胞浸润，提示VEGFD抗体在治疗类风湿性关节炎等疾病中的潜力。
3. **文献名称**: *Development of a Novel Humanized Anti-VEGFD Antibody for Solid Tumors*
**作者**: Zhang Y, et al.
**摘要**: 文章报道了一种人源化抗VEGFD抗体的临床前研究，该抗体在体外和体内均表现出对肿瘤血管生成和淋巴管生成的双重抑制作用，且毒副作用较低。
4. **文献名称**: *VEGFD Antibody as a Diagnostic Tool in Lymphedema*
**作者**: Tanaka K, et al.
**摘要**: 研究利用抗VEGFD抗体检测组织样本中的VEGFD表达水平，发现其在继发性淋巴水肿患者中显著升高，提示该抗体可作为淋巴功能障碍的生物标志物检测工具。
---
注：以上为基于领域知识的模拟文献，实际引用时需以真实发表论文为准。如需查找真实文献，建议通过PubMed或Web of Science检索关键词“VEGFD antibody”。
VEGF-D (Vascular Endothelial Growth Factor D) is a member of the VEGF family, primarily known for its role in promoting angiogenesis (blood vessel formation) and lymphangiogenesis (lymphatic vessel development). It binds to receptors VEGFR-2 and VEGFR-3. activating signaling pathways that regulate endothelial cell proliferation, migration, and survival. VEGF-D is implicated in physiological processes like tissue repair and pathological conditions, including cancer metastasis, chronic inflammation, and lymphedema.
VEGF-D antibodies are immunological tools designed to detect, quantify, or inhibit VEGF-D activity. These antibodies are widely used in research to study VEGF-D expression patterns, signaling mechanisms, and therapeutic potential. Monoclonal or polyclonal VEGF-D antibodies enable applications such as Western blotting, immunohistochemistry, ELISA, and flow cytometry. In therapeutic contexts, neutralizing VEGF-D antibodies are explored for blocking tumor-associated angiogenesis and lymphangiogenesis, thereby suppressing cancer progression and metastasis. They also hold promise in treating inflammatory diseases and lymphatic disorders by modulating vascular permeability or abnormal vessel growth.
Commercially available VEGF-D antibodies vary in specificity, host species, and clonality, requiring validation for target affinity and cross-reactivity. Their development underscores VEGF-D's significance as a biomarker and therapeutic target in vascular and lymphatic pathologies.
×
